Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
Authors
Keywords
-
Journal
DRUG SAFETY
Volume 45, Issue 8, Pages 891-908
Publisher
Springer Science and Business Media LLC
Online
2022-07-13
DOI
10.1007/s40264-022-01194-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice
- (2021) Giulia Bonaldo et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Chimeric antigen receptor T ‐cells safety: A pharmacovigilance and meta‐analysis study
- (2021) Charles Dolladille et al. AMERICAN JOURNAL OF HEMATOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
- (2021) Bianca D. Santomasso et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System
- (2021) Michele Fusaroli et al. Frontiers in Pharmacology
- CAR T-cell product performance in haematological malignancies before and after marketing authorisation
- (2020) Magdi Elsallab et al. LANCET ONCOLOGY
- Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
- (2020) Emanuel Raschi et al. Targeted Oncology
- Real-world adverse events associated with CAR T-cell therapy among adults age ≥ 65 years
- (2020) Marjorie E. Zettler et al. Journal of Geriatric Oncology
- Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis
- (2020) Avirup Guha et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Neurological adverse events following CAR T-cell therapy: a real-world analysis
- (2020) Ajeet Gajra et al. Immunotherapy
- Tisagenlecleucel in Children and Young Adults: Reverse Translational Research by Using Real-World Safety Data
- (2020) Concetta Rafaniello et al. Pharmaceuticals
- Cytokine Storm
- (2020) David C. Fajgenbaum et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)
- (2019) Raza M. Alvi et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy
- (2018) Kevin A. Hay BRITISH JOURNAL OF HAEMATOLOGY
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma
- (2016) Knut B. Smeland et al. BRITISH JOURNAL OF HAEMATOLOGY
- The IMI PROTECT project: purpose, organizational structure, and procedures
- (2016) Robert F. Reynolds et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
- (2015) Hanren Dai et al. OncoImmunology
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- A new method for constructing networks from binary data
- (2014) Claudia D. van Borkulo et al. Scientific Reports
- Data Mining of the Public Version of the FDA Adverse Event Reporting System
- (2013) Toshiyuki Sakaeda et al. International Journal of Medical Sciences
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery
- (2011) G Niklas Norén et al. STATISTICAL METHODS IN MEDICAL RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started